Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Cytokinetics (CYTK) FCF Margin (2016 - 2025)

Cytokinetics (CYTK) has disclosed FCF Margin for 16 consecutive years, with 207.79% as the latest value for Q4 2025.

  • On a quarterly basis, FCF Margin changed N/A to 207.79% in Q4 2025 year-over-year; TTM through Dec 2025 was 199.53%, a N/A change, with the full-year FY2025 number at 582.31%, down 164126.0% from a year prior.
  • FCF Margin was 207.79% for Q4 2025 at Cytokinetics, up from 8429.01% in the prior quarter.
  • In the past five years, FCF Margin ranged from a high of 766.78% in Q2 2024 to a low of 25509.26% in Q3 2023.
  • A 5-year average of 6301.59% and a median of 2659.61% in 2023 define the central range for FCF Margin.
  • Peak YoY movement for FCF Margin: crashed -2228918bps in 2023, then skyrocketed 1489850bps in 2024.
  • Cytokinetics' FCF Margin stood at 155.95% in 2021, then crashed by -3428bps to 5501.23% in 2022, then rose by 19bps to 4432.66% in 2023, then tumbled by -407bps to 22472.57% in 2024, then soared by 99bps to 207.79% in 2025.
  • Per Business Quant, the three most recent readings for CYTK's FCF Margin are 207.79% (Q4 2025), 8429.01% (Q1 2025), and 22472.57% (Q3 2024).